Panbela Therapeutics Inc. PBLA
- Market cap
- $3.4M
- P/E
- 0.0×
Follow PBLA
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 170,398.64 | 23,999.98 | 77,999.94 | 47,999.96 | 56,882.36 | 38,399.97 | 1,250.40 | 9.00 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 1,703,986.38 | 1,079,991.38 | 359,999.72 | 167,999.86 | 239,999.81 | 211,199.83 | 57,599.95 | 4,509.60 |
High Price
|
|||
| — | — | — | — | — | 5 | 6 | 6 | 7 | 8 |
Employees
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | (5) | (11) | (6) | (7) | (5) | (11) | (35) | (25) |
EBT
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | (5) | 0 | (6) | (6) | (5) | (10) | (35) | (25) |
Net Income
|
|||
| — | — | — | — | — | 2 | — | — | — | — |
Depreciation
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | (1.60) | (2.91) | (1,519.92) | (26,131.39) | (14,894.89) | (20,900.90) | (40,786.79) | (231.77) |
Earnings/Sh
|
|||
| — | — | (0.77) | (38.14) | (612.05) | (13,695.00) | (12,846.67) | (14,490.00) | (19,095.00) | (231.64) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (825.00) | 3.67 |
Capex/Sh
|
|||
| — | — | (0.77) | (38.14) | (612.05) | (13,695.00) | (12,846.67) | (14,490.00) | (19,920.00) | (227.97) |
Free CF/Sh
|
|||
| — | — | (1.49) | (41.36) | 68.72 | 6,925.00 | 28,160.00 | 20,424.00 | (10,061.25) | (43.21) |
Book Value/Sh
|
|||
| — | — | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | (2) | (3) | (2) | (3) | (4) | (7) | (15) | (25) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (1) | 0 |
Capex
|
|||
| — | — | (2) | (3) | (2) | (3) | (4) | (7) | (16) | (25) |
FCF
|
|||
| — | — | (5) | (3) | 0 | 1 | 8 | 10 | (6) | (9) |
Working Cap'
|
|||
| — | — | 3 | 2 | 0 | 0 | — | — | 6 | 5 |
Total Debt
|
|||
| — | — | 3 | 2 | (1) | (2) | (9) | (12) | 5 | 3 |
Net Debt
|
|||
| — | — | (5) | (4) | 0 | 1 | 8 | 10 | (8) | (5) |
Sh' Equity
|
|||
| — | — | (621.90%) | (2,365.79%) | (622.23%) | (245.93%) | (73.60%) | (89.35%) | (391.41%) | (301.11%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | 122.72% | 249.05% | 345.22% | (750.15%) | (96.98%) | (108.63%) | (3,230.05%) | 396.00% |
ROE
|
|||
Panbela Therapeutics Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | 0.0× | Compare |
| VRAX Virax Biolabs Group Limited | $3.3M | 0.0× | Compare |
| APVO Aptevo Therapeutics Inc. | $3.4M | 0.0× | Compare |
| UNBX UNITY Biotechnology, Inc. | $3.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IOBTQ IO Biotech, Inc. | $3.5M | 0.0× | Compare |
| BRTX Biorestorative Therapies, Inc. | $3.5M | 0.0× | Compare |
| REVB Revelation Biosciences, Inc. | $3.5M | 0.0× | Compare |
| XRTX XORTX Therapeutics Inc. | $3.2M | 0.0× | Compare |
Panbela Therapeutics Inc. (PBLA) key facts
- Panbela Therapeutics Inc. (PBLA) is a Biotechnology company in the Healthcare sector.
- As of September 24, 2026, PBLA traded at $0.01, a market capitalization of $3.4 million.
- Return on equity was 396.0% and debt-to-equity -0.23.
Panbela Therapeutics Inc. (PBLA) Latest News
14 Nov
Panbela Therapeutics, Inc. provides a business update and reports Q3 2024 financial results, including a $12.0 million financing commitment and progress in clinical trials for various cancer treatments. The strategic investment and progress in clinical trials for cancer treatments are expected to significantly impact Panbela Therapeutics Inc.'s future and market performance.
31 Oct
Panbela Therapeutics, Inc. to host third quarter 2024 earnings conference call on November 14, 2024 to discuss results for its clinical trials and pipeline assets. The announcement of clinical trial results and pipeline updates can significantly impact the company's future performance and market sentiment.
24 Sep
Panbela Therapeutics, Inc. enrolls first patient in Phase I program for STK11 mutant non-small cell lung cancer at Moffitt Cancer Center. The enrollment in Phase I program for STK11 mutant NSCLC has the potential to significantly impact Panbela Therapeutics Inc.'s future and market performance.
13 Aug
Panbela Therapeutics, Inc. provides a business update and reports Q2 2024 financial results, highlighting progress in clinical programs and corporate initiatives, as well as financial performance. The article discusses significant progress in clinical programs, corporate initiatives, and financial results, indicating a potential impact on the company's future performance.
30 Jul
Panbela Therapeutics, Inc. will host a conference call on Aug 13, 2024, to discuss second quarter results and provide updates on their pipeline assets Ivospemin and Flynpovi. The announcement of the conference call to discuss clinical trial results and pipeline updates could have a significant impact on Panbela's future performance and market sentiment.
24 Jun
Panbela Therapeutics announced third independent safety review of Phase 3 ASPIRE clinical trial, DSMB recommended continuation with no trial modification. Safety review included 395 patients, with interim survival analysis expected early 2025 due to lower-than-expected event rate. The positive safety review and potential for prolonged survival in the ASPIRE trial could significantly impact Panbela Therapeutics' future and market performance.
10 Jun
Panbela Therapeutics presented findings on the safety and efficacy of eflornithine in patients with gastric premalignant conditions at DDW conference. The presentation of positive results from the clinical trial could significantly impact Panbela's future product development and market positioning.
15 May
Panbela Therapeutics, Inc. provides business update and reports Q1 2024 financial results, highlighting progress in clinical trials and financial performance. The article discusses significant developments in clinical trials, financial results, and business updates that could have a profound impact on Panbela Therapeutics Inc.'s future trajectory and market performance.
6 May
Panbela Therapeutics announced issuance of new patent for fixed dose combination of Eflornithine and Sulindac. Issuance of new patent for lead investigational product and potential first pharmacotherapy for patients with FAP.
1 May
Panbela Therapeutics, Inc. to host first quarter 2024 earnings conference call on May 15, 2024. The announcement of the conference call to discuss first quarter results is a significant event that could impact the company's future performance and investor sentiment.
30 Apr
Panbela Therapeutics announced acceptance of eflornithine abstract for oral presentation at Digestive Disease Week. The news article discusses significant developments in Panbela's pipeline and potential impact on future market performance.
22 Apr
Panbela Therapeutics delays interim data analysis for ASPIRE trial to Q1 2025 due to lower-than-expected event rate indicating improved survival outcomes. The delay in data analysis and positive survival outcomes could significantly impact Panbela Therapeutics' future performance and market sentiment.
18 Apr
Panbela Therapeutics presented results on ivospemin/doxorubicin combination for ovarian cancer at AACR. The results presented have the potential to significantly impact Panbela's future clinical trials and market positioning in the oncology sector.
16 Apr
Panbela Therapeutics, Inc. announced transfer to OTCQB market from Nasdaq. The transfer to OTCQB market may moderately influence the company's financial performance and competitive positioning.
26 Mar
Panbela Therapeutics provides business update and reports Q4 and FY 2024 financial results. The financial results and updates on clinical trials and collaborations are expected to significantly impact the company's future trajectory.
12 Mar
Panbela Therapeutics, Inc. to host earnings conference call on March 26, 2024 to discuss fourth quarter and year-end results. The announcement of earnings results and discussion of clinical trials for key assets could significantly impact Panbela's future performance and market sentiment.
15 Feb
Panbela Therapeutics regains compliance with Nasdaq listing standards for bid price and publicly held shares requirements. Regaining compliance with Nasdaq listing standards is expected to moderately influence key areas such as financial performance and competitive positioning.
1 Feb
Panbela Therapeutics, Inc. closes $9.0 million public offering for clinical development and general corporate purposes. The significant amount raised through the public offering is expected to have a major impact on the company's future clinical development and overall market performance.
30 Jan
Panbela Therapeutics announced acceptance of SBP-101 abstract for poster presentation at AACR. The acceptance of the abstract for presentation at AACR indicates a significant impact on Panbela Therapeutics' future and market performance.
29 Jan
Panbela Therapeutics, Inc. announced pricing of a public offering of common stock and warrants, expecting to raise approximately $9.0 million. The public offering and expected proceeds of $9.0 million are significant strategic moves that could impact the company's future development and market performance.
25 Jan
Panbela Therapeutics Inc. exceeds 50% enrollment for ASPIRE trial in pancreatic cancer, anticipates interim data analysis in mid-2024. The successful enrollment and anticipated data analysis for a potentially groundbreaking treatment in pancreatic cancer could significantly impact the company's future performance and market sentiment.
18 Jan
Phase 1 study shows high dose DFMO in combination with chemotherapy may benefit heavily pretreated neuroblastoma patients. Results suggest potential significant impact on Panbela's future with promising therapeutic benefits for neuroblastoma patients.
16 Jan
Panbela Therapeutics, Inc. announces 1-for-20 reverse stock split effective January 18, 2024. The reverse stock split may have a moderately noticeable influence on the company's financial performance and market positioning.
21 Dec
Panbela Therapeutics announced exercise of warrants for $2.0 million gross proceeds. Exercise of warrants may moderately influence financial performance and competitive positioning.
18 Dec
US WorldMeds receives FDA approval for eflornithine in pediatric neuroblastoma, marking the first approval for a polyamine targeted therapy in cancer. The FDA approval of eflornithine for pediatric neuroblastoma is a significant milestone that could impact Panbela Therapeutics Inc.'s future development and market performance.
4 Dec
Panbela Therapeutics Inc. announced the publication of an abstract evaluating myeloma cell lines' viability after administering SBP-101 and DFMO polyamine inhibitors. The publication of the abstract on the evaluation of polyamine inhibitors could have a significant impact on Panbela Therapeutics Inc.'s future and market performance.
29 Nov
DSMB recommends continuation of ASPIRE Trial for Panbela Therapeutics Inc. Positive safety review and recommendation for trial continuation could significantly impact future performance and market sentiment.
9 Nov
Panbela Therapeutics, Inc. provides business update and reports Q3 2023 financial results, including collaborations, clinical trial advancements, financial updates, and future outlook. The article discusses significant developments such as collaborations, clinical trial progress, financial updates, and future catalysts that could have a major impact on Panbela Therapeutics Inc.'s future performance.
3 Nov
Panbela Therapeutics announced exercise of warrants for $1.9 million gross proceeds. Exercise of warrants and issuance of new warrants may moderately influence financial performance and competitive positioning.